Ligand Pharmaceuticals Boosts FY23 Adjusted EPS Outlook From $4.85-$5.00 To $5.10-$5.25; Est $4.98
Portfolio Pulse from Benzinga Newsdesk
Ligand Pharmaceuticals has increased its FY23 adjusted EPS outlook from $4.85-$5.00 to $5.10-$5.25, surpassing the estimated $4.98.
September 18, 2023 | 9:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ligand Pharmaceuticals has raised its FY23 adjusted EPS outlook, which is now above the estimated value.
Ligand Pharmaceuticals has increased its FY23 adjusted EPS outlook, which is a positive signal for investors. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100